Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 3, 2007, Pages 251-256

  Oshita, Fumihiro ^a   Saito, Haruhiro ^a   Yamada, Kouzo ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; NEDAPLATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPONATREMIA; LEUKOCYTE; LUNG INSUFFICIENCY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34249043829     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. New Eng J Med 346:92-98, 2002.
2. Hirsh V, Latreille J, Kreisman H, Desjardins P, Ofiara L, Whittom R, Fox S, Palayew MD, Pintos J.Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC),performance status (PS) 2, or elderly with comorbidities - a multicenter phase II trial. Lung Cancer 49:117-23, 2005.
3. Marsland TA, Garfield DH, Khan MM, Look RM, Boehm KA, Asmar L. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Lung Cancer 47:111-20. 2005.
4. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M. Nephrotoxicity of a new platinum compaound, 254S, evaluated with rat kidney cortical slices. Toxicol Lett 52:15-24, 1990.
5. Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 52:73-78, 2003.
6. Oshita F, Yamada K, Saito H, Noda K, Hamanaka N, Ikehara M, Tanaka G. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J Exp Ther Oncol 4:343-348, 2004.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 92:205-216, 2000.
8. National Cancer Institute-Common Toxicity Criteria ver.3. http://ctep.cancer.gov/reporting/CTC-3.html.
9. Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K. In vitro synergistic interactions between the cisplatin analogue nadaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechnism of this action. Clin Cancer Res 7:202-209, 2001.